Key regions: Germany, United States, India, Japan, United Kingdom
Montenegro, a small country in the Balkans, is experiencing growth in the Anti-Rheumatic Drugs market.
Customer preferences: Montenegro has an aging population, which is one of the main factors driving the growth of the Anti-Rheumatic Drugs market. The prevalence of rheumatic diseases is higher among the elderly, and as the population ages, the demand for these drugs is expected to increase. Additionally, there is a growing awareness of rheumatic diseases among the general population, which is also contributing to the growth of the market.
Trends in the market: The Anti-Rheumatic Drugs market in Montenegro is dominated by non-steroidal anti-inflammatory drugs (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs). NSAIDs are widely used for the treatment of pain and inflammation associated with rheumatic diseases, while DMARDs are used to slow down the progression of the disease. Biologic DMARDs, which are relatively new and expensive, are also gaining popularity in Montenegro, especially among patients who do not respond to conventional DMARDs.
Local special circumstances: Montenegro has a universal healthcare system, which means that all citizens have access to healthcare services and drugs, including Anti-Rheumatic Drugs. However, the availability of these drugs can be limited in some areas, particularly in rural areas. This can be attributed to the lack of specialized healthcare facilities and trained healthcare professionals in these areas.
Underlying macroeconomic factors: Montenegro is a developing country with a small economy. The healthcare sector is not a priority for the government, and as a result, the healthcare system is underfunded. This has led to a shortage of healthcare professionals and facilities, which can affect the availability and quality of healthcare services, including the Anti-Rheumatic Drugs market. Additionally, the public healthcare system is burdened with a high number of patients, which can lead to long waiting times and limited access to specialized healthcare services. As a result, some patients may opt for private healthcare services, which can be expensive and not covered by the universal healthcare system.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
